Joe McCann
Long/short equity, growth, medium-term horizon

Zohydro's Chances Of Staying On The Market

Last week Purdue Pharma released unexpected data on a new product in development: an extended release, acetaminophen-free, hydrocodone pain medication. Purdue's press release claims to have some degree of abuse deterrence incorporated into it. A major point of contention over recently launched competitor Zogenix's (NASDAQ:ZGNX) Zohydro is that it does not. In this article, I'll look to other examples of abuse deterrent formulations to try and understand how the FDA will handle this increasing political situation.

Becoming a political issue

Calls for removal of Zohydro from the market have been increasing since the FDA approved the drug. Despite a panel vote recommending against the drug's approval due to its lack of abuse deterrence, the FDA finally granted authorization....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details